The use of IORT at Merit Health Surgical Oncology
The use of IORT at Merit Health Surgical Oncology
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients
Prostate cancer
Rectal cancer
Radiobiology of hypofractionation
Enhancing cancer management: The role of oncology pharmacists in Kenya
Exploring the National Access Subcutaneous Trastuzumab Program in Kenya
Financial toxicity in the cancer patient journey
Enhancing patient care through pharmacovigilance
ESMO Magnitude of Clinical Benefit Scale (MCBS)
Guideline concordance and breast cancer management: Multi-country analysis